Property Value
dbo:abstract
  • Prima BioMed Ltd is a biotechnology company working primarily in the field of cancer immunotherapy. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 Prima acquired the privately held French immunotherapy company Immutep SA and as a result is now focused on products that work through the LAG3 immune control mechanism.Prima currently has three main products in its pipeline, all acquired with Immutep:IMP321, which is recombinant soluble LAG3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis (en)
dbo:foundingYear
  • 2001-01-01 (xsd:date)
dbo:industry
dbo:keyPerson
dbo:location
dbo:product
dbo:type
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2017-03-16 05:36:20Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 46505228 (xsd:integer)
dbo:wikiPageLength
  • 13906 (xsd:integer)
dbo:wikiPageModified
  • 2016-12-14 23:35:44Z (xsd:date)
dbo:wikiPageOutDegree
  • 70 (xsd:integer)
dbo:wikiPageRevisionID
  • 754873855 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:foundation
  • 2001 (xsd:integer)
dbp:homepage
dbp:industry
dbp:keyPeople
dbp:location
dbp:name
  • Prima BioMed Ltd (en)
dbp:products
dbp:type
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Prima BioMed Ltd is a biotechnology company working primarily in the field of cancer immunotherapy. The company was originally built on CVac, a therapeutic cancer vaccine. (en)
rdfs:label
  • Prima BioMed (en)
owl:sameAs
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Prima BioMed Ltd (en)
is dbo:wikiPageDisambiguates of
is dbo:wikiPageRedirects of
is foaf:primaryTopic of